KV Pharmaceuticals Settles Derivative Suit
St. Louis-based KV said Monday that it had reached a settlement in the derivative suit filed over the company's stock options granting practices. The company did not disclose the amount of the settlement, but said it expected insurance to cover the fees and costs associated with the case.
“Upon its finalization, the settlement of this litigation will be...
To view the full article, register now.